ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 143

Patient Rheumatoid Arthritis Data from the Real World (PARADE) Study: Preliminary Results from an Apple Researchkit™ Mobile App-Based Real World Study in the United States

Rachel Williams1, Emilia Quattrocchi2, Sarah Watts3, Sherry Wang4, Pam Berry4 and Michelle Crouthamel4, 1Real World Evidence and Epidemiology, GSK, Collegeville, PA, 2R&D Immunoinflammation, GSK, Middlesex, United Kingdom, 3GSK, Stevenage, United Kingdom, 4GSK, Collegeville, PA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: epidemiologic methods and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Epidemiology and Public Health Poster I: Rheumatoid Arthritis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Smartphone apps and sensors enable researchers to design novel endpoints and collect real world data directly from patients in a cost-effective, fast, and patient-focused approach. ResearchKit™, created by Apple in 2015, is an iOS-based, open-source platform for researchers to conduct App-based studies. We were the first pharmaceutical company to utilize the ResearchKit™ by conducting the Patient Rheumatoid Arthritis Data from the Real World (PARADE) Study. The objectives were to investigate the feasibility of utilizing a mobile app to recruit and enroll patients into a study and to gain insights about Rheumatoid Arthritis (RA) in a real world setting.

Methods: The PARADE study was conducted in the United States (US) using a customized Apple ResearchKit™ App. The PARADE App included study video, eligibility screen, electronic informed consent, and data collection. The enrolment period was July 12 through August 12, 2016. Recruitment was enhanced with advertisement on various targeted social media platforms. Participants could enroll if they were 21 years or older, spoke English, lived in the US, and had been diagnosed with RA by a doctor. Participants were asked to provide demographics, comorbidities, medications, and RA symptoms including pain, fatigue, mood and morning stiffness. Additionally, over the course of 12 weeks, participants were asked to complete validated questionnaires routinely used in RA clinical trials, namely HAQ, FACIT, and EQ-5D. All data were self-reported and collected via their iPhone.

Results: There were 1170 downloads of the PARADE App with 428 consents to participate in the study. Of these, 399 participants provided analyzable data, defined as those completing all demographic questions. The study population was 80% female, 81% Caucasian, mean age 47.9 years, and 77% college graduates. The duration of diagnosed RA included 122 (30.6%) participants with RA for <2 years, 91 (22.8%) for 2-5 years, 91 (22.8%) for 5-10 years and 95 (23.8%) for >10 years. Most bothersome RA symptoms included joint pain (87.5%), fatigue (73.5%), morning stiffness (57.5%), poor sleep (52.4%), walk and balance (32.8%), and mood variations (23.7%).  Mean pain score was 4.4 (SD 0.14) on a numerical rating scale of 0 (no pain) to 10 (worst pain imaginable). Mean scores for validated questionnaires were HAQ-DI, 1.1 (SD 0.04); Patient Global Assessment of Disease Activity, 5.4 (SD 0.14) (0=I don’t feel arthritis to 10=Arthritis affects me severely); EQ-5D, 0.6983 (SD 0.00822), and FACIT, 25.5 (SD 0.66). RA medications are listed in the Table.

Conclusion: The PARADE study was the first Pharma-sponsored study in which real world patients could self-recruit, consent, enroll, and report data entirely via their iPhone using a ResearchKit™ App. This study successfully demonstrated the feasibility of this novel technology to gather insights into RA from a real world perspective.

Current RA medications among PARADE study participants

Proportion of population that answered this question (n=388)

Painkillers

170 (43.8%)

NSAIDs

194 (50.0%)

Corticosteroids

117 (30.2%)

Methotrexate

155 (39.9%)

Azathioprine

5 (1.3%)

Auranofin

1 (0.3%)

Chloroquine

1 (0.3%)

Hydroxychloroquine

107 (27.6%)

Leflunomide

30 (7.7%)

Mycophenolate

3 (0.8%)

Sulfasalazine

29 (7.5%)

Abatacept

29 (7.5%)

Adalimumab

42 (10.8%)

Certolizumab

10 (2.6%)

Etanercept

34 (8.8%)

Golimumab

11 (2.8%)

Infliximab

16 (4.1%)

Rituximab

11 (2.8%)

Tocilizumab

13 (3.4%)

Tofacitinib

18 (4.6%)

Others

40 (10.3%)



Disclosure: R. Williams, GSK, 3; E. Quattrocchi, GSK, 3; S. Watts, gsk, 3; S. Wang, gsk, 3; P. Berry, gsk, 3; M. Crouthamel, gsk, 3.

To cite this abstract in AMA style:

Williams R, Quattrocchi E, Watts S, Wang S, Berry P, Crouthamel M. Patient Rheumatoid Arthritis Data from the Real World (PARADE) Study: Preliminary Results from an Apple Researchkit™ Mobile App-Based Real World Study in the United States [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/patient-rheumatoid-arthritis-data-from-the-real-world-parade-study-preliminary-results-from-an-apple-researchkit-mobile-app-based-real-world-study-in-the-united-states/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-rheumatoid-arthritis-data-from-the-real-world-parade-study-preliminary-results-from-an-apple-researchkit-mobile-app-based-real-world-study-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology